Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly

JAMA Surgery

Volumn 149, Issue 12, 2014, Pages 1244-1253

  Shirvani, Shervin M ^a,b   Jiang, Jing ^a   Chang, Joe Y ^a   Welsh, James ^a   Likhacheva, Anna ^b   Buchholz, Thomas A ^a   Swisher, Stephen G ^a   Smith, Benjamin D ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Banner MD Anderson Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CANCER MORTALITY; CANCER REGISTRY; CANCER SPECIFIC SURVIVAL; FEMALE; HUMAN; LUNG LOBECTOMY; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MEDICARE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; RADIOTHERAPY; STEREOTACTIC ABLATIVE RADIOTHERAPY; SUBLOBAR RESECTION; SURVIVAL RATE; SURVIVAL TIME; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; INCIDENCE; LUNG NEOPLASMS; MULTICENTER STUDY; PROCEDURES; RADIOSURGERY; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; TRENDS; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PNEUMONECTOMY; RADIOSURGERY; RETROSPECTIVE STUDIES; RISK FACTORS; SEER PROGRAM; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; UNITED STATES;

EID: 84919667191     PISSN: 21686254     EISSN: 21686262     Source Type: Journal    
DOI: 10.1001/jamasurg.2014.556     Document Type: Article

References (39)

1. Aberle DR, Adams AM, Berg CD, et al; National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5): 395-409.
2. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27(17): 2758-2765.
3. Ginsberg RJ, Rubinstein LV; Lung Cancer Study Group. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Ann Thorac Surg. 1995;60(3): 615-623.
4. Martin-Ucar AE, Nakas A, Pilling JE, West KJ, Waller DA. A case-matched study of anatomical segmentectomy versus lobectomy for stage I lung cancer in high-risk patients. Eur J Cardiothorac Surg. 2005;27(4): 675-679.
5. SchuchertMJ, Pettiford BL, Keeley S, et al. Anatomic segmentectomy in the treatment of stage I non-small cell lung cancer. Ann Thorac Surg. 2007; 84(3): 926-933.
6. El-Sherif A, Gooding WE, Santos R, et al. Outcomes of sublobar resection versus lobectomy for stage I non-small cell lung cancer: a 13-year analysis. Ann Thorac Surg. 2006;82(2): 408-416.
7. Kilic A, SchuchertMJ, Pettiford BL, et al. Anatomic segmentectomy for stage I non-small cell lung cancer in the elderly. Ann Thorac Surg. 2009; 87(6): 1662-1668.
8. Okada M, Koike T, Higashiyama M, Yamato Y, Kodama K, Tsubota N. Radical sublobar resection for small-sized non-small cell lung cancer: a multicenter study. J Thorac Cardiovasc Surg. 2006;132(4): 769-775.
9. Surgery with or without internal radiation therapy compared with stereotactic body radiation therapy in high risk patients with stage I non-small cell lung cancer. http://clinicaltrials.gov/show/NCT01336894. Accessed January 20, 2014.
10. Randomized study to compare CyberKnife stereotactic radiotherapy with surgical resection in stage I non-small cell lung cancer (STARS). http://clinicaltrials.gov/ct2/show/NCT00840749. Accessed June 1, 2013.
11. Trial of either surgery or stereotactic radiotherapy for early stage (IA) lung cancer (ROSEL). http://clinicaltrials.gov/ct2/show/NCT00687986. Accessed June 1, 2013.
12. Comparison of different types of surgery in treating patients with stage IA non-small cell lung cancer. http://clinicaltrials.gov/show/NCT00499330. Accessed July 1, 2013.
13. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8)(suppl): IV-3-IV-18.
14. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46(10): 1075-1079, 1081-1090.
15. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53 (12): 1258-1267.
16. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5): 373-383.
17. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45 (6): 613-619.
18. Davidoff AJ, Tang M, Seal B, Edelman MJ. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13): 2191-2197.
19. Smith BD, Pan IW, Shih YC, et al. Adoption of intensity-modulated radiation therapy for breast cancer in the United States. J Natl Cancer Inst. 2011; 103(10): 798-809.
20. Doria-Rose VP, Marcus PM. Death certificates provide an adequate source of cause of death information when evaluating lung cancer mortality: an example from the Mayo Lung Project. Lung Cancer. 2009;63(2): 295-300.
21. Klein JP, Moeschberger ML. Survival Analysis Techniques for Censored and Truncated Data. New York, NY: Springer; 2003.
22. BrookhartMA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Stürmer T. Variable selection for propensity score models. Am J Epidemiol. 2006;163 (12): 1149-1156.
23. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25): 3083-3107.
24. D'Agostino RB Jr. Propensity scoremethods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17 (19): 2265-2281.
25. Donington JS. Point: are limited resections appropriate in non-small cell lung cancer? yes. Chest. 2012;141(3): 588-590, 593-584.
26. Chamogeorgakis T, Ieromonachos C, Georgiannakis E, Mallios D. Does lobectomy achieve better survival and recurrence rates than limited pulmonary resection for T1N0M0 non-small cell lung cancer patients? Interact Cardiovasc Thorac Surg. 2009;8(3): 364-372.
27. Detterbeck FC. Counterpoint: are limited resections appropriate in non-small cell lung cancer? no: don't overdo it, and don't get confused. Chest. 2012;141(3): 590-593.
28. Mery CM, Pappas AN, Bueno R, et al. Similar long-term survival of elderly patients with non-small cell lung cancer treated with lobectomy or wedge resection within the Surveillance, Epidemiology, and End Results database. Chest. 2005;128(1): 237-245.
29. Kates M, Swanson S, Wisnivesky JP. Survival following lobectomy and limited resection for the treatment of stage I non-small cell lung cancer-1 cm in size: a review of SEER data. Chest. 2011;139 (3): 491-496.
30. Wisnivesky JP, Henschke CI, Swanson S, et al. Limited resection for the treatment of patients with stage IA lung cancer. Ann Surg. 2010;251(3): 550-554.
31. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11): 1070-1076.
32. Grills IS, Mangona VS, Welsh R, et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol. 2010;28(6): 928-935.
33. Crabtree TD, Denlinger CE, Meyers BF, et al. Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2010;140(2): 377-386.
34. Palma D, Visser O, Lagerwaard FJ, Belderbos J, Slotman B, Senan S. Treatment of stage I NSCLC in elderly patients: a population-based matched-pair comparison of stereotactic radiotherapy versus surgery. Radiother Oncol. 2011;101(2): 240-244.
35. Shirvani SM, Jiang J, Chang JY, et al. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys. 2012;84 (5): 1060-1070.
36. Lagerwaard FJ, Verstegen NE, Haasbeek CJ, et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2012;83(1): 348-353.
37. Onishi H, Shirato H, Nagata Y, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys. 2011;81(5): 1352-1358.
38. Pan H, Simpson DR, Mell LK, Mundt AJ, Lawson JD. A survey of stereotactic body radiotherapy use in the United States. Cancer. 2011;117(19): 4566-4572.
39. Bosco JL, Silliman RA, Thwin SS, et al. A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol. 2010;63(1): 64-74.